TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39018515

Group type: EXPERIMENTAL
Intervention: Tailored dose-dense chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy
Number of subjects: 0
Study: 39018532

Group type: EXPERIMENTAL
Intervention: 5-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 5 days)
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: 10-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 10 days)
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Placebo (for 5 or 10 days)
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Adverse events across all groups
Number of subjects: 2736
Study: 39018533

Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa (50 IU per kilogram of body weight) for 52 weeks
Number of subjects: 74
Study: 39018531

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 520

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 520
Study: 39018898

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) pregabalin (150 mg once daily)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Immediate-release (IR) pregabalin (75 mg twice daily)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparison of SR pregabalin to IR pregabalin
Number of subjects: 130
Study: 39019103

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 308
Study: 39019119

Group type: EXPERIMENTAL
Intervention: Low BC (392 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High BC (784 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 39019150

Group type: EXPERIMENTAL
Intervention: Tebentafusp
Number of subjects: 378

Group type: COMPARATOR
Intervention: Investigator's choice
Number of subjects: 378
Study: 39019156

Group type: EXPERIMENTAL
Intervention: Peer Network Counseling-txt (PNC-txt)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1078
Study: 39019203

Group type: EXPERIMENTAL
Intervention: Stellarex Drug-Coated Balloon (2 µg/mm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39019496

Group type: EXPERIMENTAL
Intervention: HEARTS intervention
Number of subjects: 3935
Study: 39019530

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 39019541

Group type: EXPERIMENTAL
Intervention: Cdyn-guided PEEP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional PEEP
Number of subjects: 60
Study: 39019622

Group type: EXPERIMENTAL
Intervention: Pre-consent incentive (postage stamps)
Number of subjects: 600258

Group type: COMPARATOR
Intervention: Post-consent incentive (postage stamps)
Number of subjects: 600258
Study: 39019639

Group type: EXPERIMENTAL
Intervention: Implant-based breast reconstruction
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Autologous breast reconstruction
Number of subjects: 124
Study: 39019657

Group type: EXPERIMENTAL
Intervention: Heterologous BNT162b2 + mRNA-1273 vaccination schedule
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Low dose of mRNA-1273
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Intraderal vaccination
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Adapted vaccination schedules after first booster vaccination
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Booster vaccination (dose or brand unspecified)
Number of subjects: 566
Study: 39019698

Group type: EXPERIMENTAL
Intervention: Individualized starting dose (ISD) regimen (200 mg QD for BW <77 kg or PLT <150,000/µL; 300 mg QD for BW ≥77 kg and PLT ≥150,000/µL)
Number of subjects: 1442

Group type: COMPARATOR
Intervention: 300 mg fixed starting dose (FSD)
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Higher niraparib exposure (AUC)
Number of subjects: 1442
Study: 39019875

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day (D-50)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day (D-100)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 39019979

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, prednisone, and apalutamide (AAPA) for 8 weeks
Number of subjects: 186
Study: 39020305

Group type: EXPERIMENTAL
Intervention: Cenegermin t.i.d. (20 mcg/mL, 3 times daily)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Cenegermin b.i.d. (20 mcg/mL, 2 times daily)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Vehicle (once daily or t.i.d.)
Number of subjects: 247
Study: 39020307

Group type: EXPERIMENTAL
Intervention: STOPCOV intervention delivered by community health workers (CHWs) including face masks, sanitiser, bleach, and written information, followed by regular telephonic follow-up.
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: STOPCOV intervention.
Number of subjects: 326
Study: 39020348

Group type: EXPERIMENTAL
Intervention: USM-IAM-based counselling
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard counselling (SCG)
Number of subjects: 90
Study: 39020405

Group type: EXPERIMENTAL
Intervention: Getting Better Bite by Bite (GBBB) intervention along with routine care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study: 39020409

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET) for primary M3 occlusion
Number of subjects: 11
Study: 39020446

Group type: EXPERIMENTAL
Intervention: One or two additional doses of COVID-19 vaccines 3 months apart
Number of subjects: 0
Study: 39020503

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR) treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 66
Study: 39020518

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy and neoadjuvant chemotherapy in combination with sindilizumab
Number of subjects: 588

Group type: COMPARATOR
Intervention: Short-course radiotherapy and neoadjuvant chemotherapy
Number of subjects: 588
Study: 39021216

Group type: EXPERIMENTAL
Intervention: Intra-operative urine output (UO)
Number of subjects: 1184
Study: 39021272

Group type: EXPERIMENTAL
Intervention: Combined nivolumab and ipilimumab (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined nivolumab and ipilimumab with SBRT (n=25)
Number of subjects: 50
Study: 39021478

Group type: EXPERIMENTAL
Intervention: Low-cost kitchen with improved cookstove
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Traditional cookstoves (Control)
Number of subjects: 1267
Study: 39021646

Group type: EXPERIMENTAL
Intervention: MAEva program (Mindfulness meditation, Acceptance, and Commitment to values program)
Number of subjects: 40
Study: 39021751

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 17
Study: 39022168

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 74

Group type: COMPARATOR
Intervention: Rilonacept interruption
Number of subjects: 74
Study: 39022429

Group type: EXPERIMENTAL
Intervention: STOP group (40,000 IU subcutaneous EPO combined with 20 mg/kg intravenous ferric carboxymaltose if Hb < 13 g/dL the day before surgery or at ICU admission, and RBC transfusion if Hb ≤ 8 g/dL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (standard care without the bundle of care)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: STOP group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 39022641

Group type: EXPERIMENTAL
Intervention: Fun For Wellness intervention
Number of subjects: 0
Study: 39022700

Group type: EXPERIMENTAL
Intervention: MicroNET-covered stent
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitor use as intraarterial (IA) bolus + intravenous (IV) infusion
Number of subjects: 75
Study: 39022726

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on ipsilesional primary motor cortex (M1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on ipsilesional ventral premotor cortex
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on contralesional M1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-frequency rTMS on contralesional M1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All interventions (high-frequency rTMS protocols)
Number of subjects: 120
Study: 39022796

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22, administered in 28-day cycles for a total of 12 cycles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone regimen
Number of subjects: 23
Study: 39022823

Group type: EXPERIMENTAL
Intervention: ILR screening
Number of subjects: 6004

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 6004
Study: 39022889

Group type: EXPERIMENTAL
Intervention: Horse Riding Simulator (HRS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 32
Study: 39023055

Group type: EXPERIMENTAL
Intervention: PRADO-IC program
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 404
Study: 39023063

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: No oral anticoagulants (OAC)
Number of subjects: 1059
Study: 39023092

Group type: EXPERIMENTAL
Intervention: Imlifidase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plasmapheresis (PLEX)
Number of subjects: 30
Study: 39023141

Group type: EXPERIMENTAL
Intervention: Early catheter ablation within 4 weeks after randomization
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 1548
Study: 39023142

Group type: EXPERIMENTAL
Intervention: CaRi-Heart Risk
Number of subjects: 2300000

Group type: COMPARATOR
Intervention: Standard of care (not explicitly defined)
Number of subjects: 2300000
Study: 39023253

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy for 2 years, followed by endocrine therapy for a total of at least 5 years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy only for at least 5 years.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy only
Number of subjects: 0
Study: 39023287

Group type: EXPERIMENTAL
Intervention: Durvalumab + Oleclumab
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Durvalumab + Monalizumab
Number of subjects: 999

Group type: COMPARATOR
Intervention: Durvalumab + Placebo
Number of subjects: 999
Study: 39023393

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 119
Study: 39023418

Group type: EXPERIMENTAL
Intervention: Guideline-directed monitoring and management practices
Number of subjects: 435971

Group type: EXPERIMENTAL
Intervention: Prescriptions for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins
Number of subjects: 435971

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitors
Number of subjects: 435971

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements
Number of subjects: 435971

Group type: EXPERIMENTAL
Intervention: Overall standard of care
Number of subjects: 435971
Study: 39023538

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Heparin anticoagulation (HA)
Number of subjects: 247

Group type: COMPARATOR
Intervention: No anticoagulation (NA)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: RCA
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Dialyser surface area
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Left internal jugular vein vascular access site
Number of subjects: 247
Study: 39023547

Group type: EXPERIMENTAL
Intervention: Symptom Management and Survivorship Handbook (SMSH)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Symptom Management and Survivorship Handbook (SMSH) + Telephone Interpersonal Counseling (TIPC)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Lower intensity SMSH
Number of subjects: 462
Study: 39023568

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39023880

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg orally once daily for up to 52 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo orally once daily for up to 52 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 39023893

Group type: COMPARATOR
Intervention: Enhanced Personalized Feedback (EPF) only
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Silvercloud only (CBT-based)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Silvercloud plus EPF
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Headspace only (mindfulness-based)
Number of subjects: 2079

Group type: EXPERIMENTAL
Intervention: Headspace plus EPF
Number of subjects: 2079
Study: 39023900

Group type: EXPERIMENTAL
Intervention: 90 minutes per week of exercise therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 150 minutes per week of exercise therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 225 minutes per week of exercise therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 300 minutes per week of exercise therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 375 minutes per week of exercise therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 450 minutes per week of exercise therapy
Number of subjects: 53
Study: 39023984

Group type: EXPERIMENTAL
Intervention: Web-based cognitive bias modification for interpretation (CBM-I)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Active psychoeducation
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: CBM-I with low-intensity telecoaching
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: CBM-I without coaching
Number of subjects: 1234
Study: 39024000

Group type: EXPERIMENTAL
Intervention: Exergame-RFA plus standard care
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 96
Study: 39024005

Group type: EXPERIMENTAL
Intervention: Safety Incident Report System for Students
Number of subjects: 223
Study: 39024037

Group type: EXPERIMENTAL
Intervention: Nivolumab (four cycles of 240 mg every 2 weeks, thereafter 480 mg every 4 weeks)
Number of subjects: 130
Study: 39024237

Group type: EXPERIMENTAL
Intervention: Optimal Health Program (OHP)
Number of subjects: 30
Study: 39024364

Group type: EXPERIMENTAL
Intervention: Early norepinephrine (NE) administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 39024366

Group type: EXPERIMENTAL
Intervention: Health and Well-Being Committees (HaWCs) intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control sites (no intervention)
Number of subjects: 1200
Study: 39024543

Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec (6 × 10^13 vg/kg infusion)
Number of subjects: 134
Study: 39024542

Group type: EXPERIMENTAL
Intervention: Once-weekly carfilzomib (56 mg/m2) plus lenalidomide and dexamethasone (KRd56)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27)
Number of subjects: 454
Study: 39024777

Group type: EXPERIMENTAL
Intervention: Pyrotinib-based regimen
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pyrotinib-based regimen as second-line therapy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pyrotinib-based regimen as third-or-post-line therapy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Brain radiotherapy (BRT)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Not applicable (adverse events)
Number of subjects: 137
Study: 39024845

Group type: EXPERIMENTAL
Intervention: Active PSI-rTMS (10 Hz, 80% resting motor threshold, 5 daily sessions for 1 week, followed by weekly maintenance for 7 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham PSI-rTMS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Active PSI-rTMS
Number of subjects: 25
Study: 39024964

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39025065

Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 77
Study: 39025066

Group type: EXPERIMENTAL
Intervention: ABO1020 (15 μg per dose, 2 doses, administered 28 days apart)
Number of subjects: 14138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14138

Group type: EXPERIMENTAL
Intervention: ABO1020 (1 or 2 doses)
Number of subjects: 14138

Group type: EXPERIMENTAL
Intervention: ABO1020
Number of subjects: 14138
Study: 39025092

Group type: EXPERIMENTAL
Intervention: Initial oral antibiotics (coformulated amoxicillin 100 mg/kg per day and clavulanic acid 12.5 mg/kg per day for patients younger than 5 years; dicloxacillin 200 mg/kg per day for patients aged 5 years or older)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Initial intravenous antibiotics (ceftriaxone 100 mg/kg per day in one dose)
Number of subjects: 248
Study: 39025100

Group type: EXPERIMENTAL
Intervention: Extended mesenteric resection
Number of subjects: 139

Group type: COMPARATOR
Intervention: Mesenteric sparing resection
Number of subjects: 139
Study: 39025255

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39025264

Group type: EXPERIMENTAL
Intervention: nano-CBD cream
Number of subjects: 19

Group type: COMPARATOR
Intervention: vehicle cream
Number of subjects: 19
Study: 39025698

Group type: EXPERIMENTAL
Intervention: VAX-24 2.2 mcg dose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Prevnar 20® (PCV20)
Number of subjects: 200
Study: 39025785

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ticagrelor 90 mg
Number of subjects: 50
Study: 39025812

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention including a patient information leaflet and key questions diagram, and an option grid.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Evidence-based recommendations for treatment following ACL rupture.
Number of subjects: 8
Study: 39025948

Group type: EXPERIMENTAL
Intervention: BEMPEG + NIVO
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIVO
Number of subjects: 0
Study: 39025971

Group type: EXPERIMENTAL
Intervention: Milvexian (200 mg; twice daily for 5 days) with aspirin (325 mg for 5 days)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Milvexian (200 mg; twice daily for 5 days) with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Milvexian (200 mg; twice daily for 5 days) without aspirin or clopidogrel
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo with aspirin (325 mg for 5 days)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo with clopidogrel (Day 1: 300 mg; Days 2-5: 75 mg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo without aspirin or clopidogrel
Number of subjects: 113
Study: 39026124

Group type: EXPERIMENTAL
Intervention: SPIKES protocol (nurses trained for 1 hour)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine care (standard of care)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: SPIKES protocol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 136
Study: 39026154

Group type: EXPERIMENTAL
Intervention: OMT + CAVI (n=8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: OMT (n=10)
Number of subjects: 18
Study: 39026165

Group type: EXPERIMENTAL
Intervention: Granisetron transdermal delivery system (GTDS) combined with Dexamethasone
Number of subjects: 54
Study: 39026172

Group type: EXPERIMENTAL
Intervention: Fetuin-A assessment in MASLD patients
Number of subjects: 100
Study: 39026197

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (33.5 ± 0.5 C) for 72 hours
Number of subjects: 426

Group type: COMPARATOR
Intervention: Normothermia (37.0 ± 0.5 C) for 72 hours
Number of subjects: 426
Study: 39026236

Group type: EXPERIMENTAL
Intervention: ATSB deployment (intervention)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no ATSB deployment)
Number of subjects: 20
Study: 39026266

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (40 min daily over three consecutive days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Midazolam (active placebo, 40 min daily over three consecutive days)
Number of subjects: 33
Study: 39026289

Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI before SRS and follow-up MRIs every 3 months for 24 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI protocol including T2-weighted, contrast-enhanced T1-weighted imaging, diffusion-weighted imaging, and dynamic susceptibility contrast imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DICE similarity coefficients calculation
Number of subjects: 0
Study: 39026306

Group type: EXPERIMENTAL
Intervention: Aripiprazole oral solution (1 mg/mL, range: 2-20 mg, starting dose of 2 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 39026547

Group type: EXPERIMENTAL
Intervention: ReFerm enema
Number of subjects: 30
Study: 39026552

Group type: EXPERIMENTAL
Intervention: New clinically implemented diagnostic imaging modalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging stratification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment requirements in GCA patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment needs in PMR patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic role of imaging
Number of subjects: 0
Study: 39026620

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) as a biological therapy for preventing postoperative AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study: 39026628

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6796